WC
ANTH

Wexford Capital’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Wexford Capital’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-18,203
Closed -$459K – 332
2016
Q3 		$459K Hold
18,203
– – 0.07% 140
2016
Q2 		$450K Buy
18,203
+9,375
+106% +$265K 0.08% 96
2016
Q1 		$256K Buy
+8,828
New +$240K 0.05% 97
2015
Q3 		– Sell
-22,188
Closed -$1.53M – 114
2015
Q2 		$1.53M Buy
22,188
+7,375
+50% +$341K 0.41% 36
2015
Q1 		$530K Buy
+14,813
New +$438K 0.15% 52

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wexford Capital's ANTH Position: Q4 2016 in Review

Wexford Capital sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2016, closing a stake of 18,203 shares — an estimated $459K sold.

Wexford Capital first reported a position in ANTH in Q1 2015 and held it in 5 quarters. The position peaked at $1.53M in Q2 2015. 72 funds tracked by Wall St. Rank hold ANTH as of Q4 2016.

  • Wexford Capital reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Wexford Capital sold 18,203 Anthera Pharmaceuticals, Inc. shares in Q4 2016, an estimated $459K.
  • Wexford Capital first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
  • Wexford Capital's Anthera Pharmaceuticals, Inc. position peaked at $1.53M in Q2 2015.
  • 72 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2016.

Based on Wexford Capital's 13F filing for Q4 2016, filed 14 Feb 2017.